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Neutrophil elastase (NE) activity is increased in bronchiectasis and may play a role in this
condition. We wished to determine the effect of AZD9668, a selective oral inhibitor of NE.
Efficacy and safety of AZD9668 60 mg twice daily over 4 weeks were evaluated in a rando-
mised, double-blind, placebo-controlled, parallel-group, Phase II, signal-searching study in
patients with bronchiectasis. Outcome measures included: waking and post-waking sputum
neutrophil counts; lung function tests; 24-h sputum weight; BronkoTest diary card data; St
George’s Respiratory Questionnaire for COPD patients (SGRQ-C); sputum NE activity; inflamma-
tory biomarker levels; desmosine levels; adverse events, safety haematology and biochem-
istry. AZD9668 levels in plasma and sputum were measured to confirm exposure.
Thirty-eight patients were randomised: 16 to placebo and 22 to AZD9668. There was no
change in sputum neutrophils with AZD9668. Forced expiratory volume in 1 s improved by
100 mL in the AZD9668 group compared with placebo (pZ 0.006). Significant changes (defined
a priori as p < 0.1) in favour of AZD9668 were also seen in slow vital capacity, plasma121 6978257; fax: þ44 0121 6978256.
hb.nhs.uk, r.a.stockley@bham.ac.uk (R. Stockley).
3 Elsevier Ltd. All rights reserved.
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AZD9668 in patients with bronchiectasis 525interleukin-8, and post-waking sputum interleukin-6 and Regulated on Activation, Normal
T-cell Expressed and Secreted levels. Non-significant changes in favour of AZD9668 were seen
in other lung function tests, sputum weight and the SGRQ-C. AZD9668 was well tolerated.
In this small signal-searching study, 4 weeks’ treatment with AZD9668 improved lung func-
tion in patients with bronchiectasis and there were trends for reductions in sputum inflamma-
tory biomarkers. Larger studies of longer duration would be needed to confirm the potential
benefits of this agent in bronchiectasis.
Registration: NCT00769119.
ª 2013 Elsevier Ltd. All rights reserved.Introduction
Bronchiectasis is a disease characterised by localised,
irreversible dilatation of parts of the bronchial tree, caused
by destruction of the structural components of the bron-
chial wall resulting from a vicious cycle of transmural
infection and inflammation.1 It is associated with varying
degrees of airway obstruction and impaired clearance of
secretions.
Neutrophils play a key role in the inflammation in
bronchiectasis. Airway neutrophilia results in high concen-
trations of neutrophil proteases, a phenomenon implicated
in the pathogenesis of several inflammatory lung diseases
including bronchiectasis associated with cystic fibrosis2,3
and non-cystic fibrosis bronchiectasis.4,5 Neutrophil elas-
tase (NE) is a serine protease found in high concentrations
in neutrophils6 that is able to degrade extracellular matrix
and proteins, damaging the lung parenchyma and airway
walls.7e9 Control of NE activity might help to down-regulate
proteolytic lung destruction and slow disease progression in
bronchiectasis. NE also has pro-inflammatory effects10,11
and stimulates mucus secretion12e14 as well as inhibiting
mucociliary clearance.3 Hence, it is plausible that an NE
inhibitor could also reduce inflammatory mediators and
improve symptoms and health-related quality of life
(HRQoL) in bronchiectasis.
AZD9668 is a novel, orally active reversible inhibitor of
human NE.15 The safety, tolerability and pharmacokinetics
of AZD9668 have previously been investigated in healthy
volunteers and patients with chronic obstructive pulmonary
disease (COPD).16 AZD9668 at a dose of 60 mg twice daily
(bid) for 14 days was well tolerated and achieved blood
levels adequate to cause >90% inhibition of zymosan-
stimulated NE activity in whole blood ex vivo.
The aim of this signal-searching study (NCT00769119)
was to assess the efficacy and safety of AZD9668 in patients
with bronchiectasis, and to examine its effect on
biomarkers of inflammation and tissue damage.Methods
Design
This was a randomised, double-blind, placebo-controlled,
parallel-group,Phase II signal-searching study (NCT00769119)
to investigate the efficacy of 28 days’ dosing with oral
AZD9668 in patients with bronchiectasis. After a run-in
period lasting up to 3 weeks, patients were randomised toreceiveoral AZD9668ormatchingplacebo.Forassessmentsof
sputum weight and biomarkers, a baseline 24-h sputum
collection and two waking (first expectoration on rising,
brought to study centre as soon as possible) and two post-
waking (subsequent expectorant collected over up to 2 h)
sputum samples were obtained during the week prior to
randomisation. Sputumsamplingwas repeatedduring the last
week on treatment and at the end of Visit 4. The study design
is shown in Fig. 1 of the Supplementary Material and sample
collection and assessment information at each visit are
detailed in the Supplementary Methods. The study was con-
ducted at four centres in the UK and six in Canada.
Patients
Patients were included in the study if they: were male, or
female of non-child bearing potential; were aged between
18 and 80 years, with a clinical diagnosis of idiopathic or
post-infective bronchiectasis; had a history of chronic
expectoration on most days of most weeks of the year; were
clinically stable for 6 weeks prior to study entry; and had
normal laboratory values at enrolment, unless the investi-
gator considered an abnormality to be clinically irrelevant.
Exclusion criteria included: participation (defined as
administration of at least one dose of investigational
product) in another clinical study within 12 weeks of
enrolment; bronchiectasis of other aetiologies.
Treatments
Patients were randomised using a 1:1 computer-based
randomisation scheme (block size 4) to receive either
AZD9668 (60 mg bid) or matching placebo tablets for
28 days. Patients were given sufficient tablets to allow
dosing at 60 mg bid until Visit 3 (Day 14  2 days). At Visit 3,
the remaining study drug was dispensed, to allow 60 mg bid
until Visit 4 (Day 28  2 days).
Assessments
The primary efficacy variables for this study were: absolute
and percentage neutrophil counts in waking and post-
waking sputum samples; change from baseline (Visit 1a or
1b) in 24-h sputum weight; change from randomisation in
pre-bronchodilator (in order to detect any beneficial or
detrimental effect of the drug) forced expiratory volume in
1 s [FEV1], slow vital capacity [SVC], forced vital capacity
[FVC], forced expiratory flow between 25 and 75%
[FEF25e75%] of FVC; BronkoTest
 diary card data (including
526 R. Stockley et al.morning and evening peak expiratory flow [PEF], symptom
scores and reliever medication use); and the change from
randomisation in HRQoL measured using the St George’s
Respiratory Questionnaire for COPD patients (SGRQ-C). The
SGRQ has been previously validated for bronchiectasis.17
Sputum was processed at 4 C within 2 h of expectora-
tion, where possible (see Supplementary Material for
further details). Preparation of the cytospin slides and an
assessment of their viability and quality were conducted at
each local investigation site. All slides were subsequently
shipped to the Institute for Lung Health, Glenfield Hospital,
Leicester, UK and analysed for absolute and percentage
neutrophil counts.
Secondary efficacy variables included: NE activity in
spontaneous sputum; inflammatory biomarkers in sputum
(tumour necrosis factor-alpha [TNFa], interleukin [IL]-6,
IL-8 [CXCL8], IL-1 beta [IL-1b], leukotriene B4 [LTB-4],
Regulated on Activation, Normal T-cell Expressed and
Secreted [RANTES (CCL5)] and monocyte chemoattractant
protein-1 [MCP-1 (CCL2)]); blood inflammatory biomarkers
(including TNFa, IL-6, IL-8 and IL-1b); urinary (total and
free) desmosine (creatinine normalised)18; safety (reported
adverse events [AEs], clinical laboratory evaluations,
vital signs, electrocardiogram [ECG] monitoring, physical
examinations and sputum cultures); and pharmacokinetic
parameters (AZD9668 concentrations in plasma and
sputum). Plasma (total) desmosine was measured as an
exploratory outcome.
NE activity and desmosine and creatinine levels were
analysed by Clinical Pharmacology & DMPK, AstraZeneca
R&D, Charnwood, UK. All other sputum and plasma
inflammatory biomarkers, except for sputum IL-8 and
LTB-4, were analysed at Biosciences, AstraZeneca R&D,
Lund, Sweden. For biomarker analyses, the supernatant
from processed sputum was stored frozen at 20 C until
transported and analysed using an AstraZeneca custom-
made 5-plex immunoassay, purchased from Meso Scale
Discovery, Gaithersburg, MD, USA. Sputum IL-8 and LTB4
were analysed at Quotient Bioresearch Ltd, Fordham,
Cambridgeshire, UK using an R&D Systems ELISA kit and
a Cayman Chemicals Enzyme Immunoassay kit, respec-
tively. For assessment of plasma biomarkers, plasma was
collected in appropriate tubes and samples were stored at
or below 20 C. Assay of plasma biomarkers was per-
formed using the Human ProInflammatory-4 II Ultra-
Sensitive Kit #K11025C-2, which was purchased from Meso
Scale Discovery, Gaithersburg, MD, USA. High sensitivity-
CRP was analysed using an immuno-turbidimetric test using
an Olympus System CRP latex kit. Amyloid-A was assessed
at Quotient Bioresearch Ltd, Fordham, Cambridgeshire, UK
using an Anogen ELISA kit (Cat No. EL10015).
Haematology, clinical chemistry and urinalysis were
conducted for all UK investigational sites by Covance
Central Laboratory Services SA, Geneva, Switzerland. For
Canadian sites, these parameters were assessed by Cova-
nce Central Laboratory Services, Inc., Indianapolis, IN, USA.
AZD9668 concentrations in sputum supernatant were
analysed by Clinical Pharmacology & DMPK, AstraZeneca
R&D, Lund, Sweden. The concentration of AZD9668 in
plasma was assessed by York Bioanalytical Solution,
York, UK, on behalf of Clinical Pharmacology & DMPK,
AstraZeneca.All sample analysis was undertaken and the data locked
prior to unblinding the study.
Statistical analyses
This study was exploratory and therefore the sample size
was not based on obtaining power to detect specific
effects. However, a sample size of 40 patients (20 per
treatment group) was judged to be sufficient to detect
a 50% decrease in neutrophil numbers with a power of 80%,
assuming a standard deviation of 1 on logged data. As this
was a signal-searching study, a 2-sided p-value of <0.1 was
considered significant. There was no adjustment for
multiplicity.
Analysis of variance (ANOVA) was used to compare
AZD9668 with placebo for the neutrophil count and
biomarker data. Baseline data (on a log scale) and country
were included as covariates. For the other efficacy
outcomes, ANOVA was used, where treatment and country
were fixed factors and baseline values were the covariate.
The primary efficacy analysis population included all
patients who received at least one dose of study drug and
for whom post-randomisation efficacy data were available.
The safety analysis set included all patients who received
at least one dose of study drug and for whom any post-dose
data were available.
Post-hoc analyses
Sputum biomarker data were subjected to post-hoc anal-
yses to determine if adjusting for sputum weight
(biomarker concentration  sample weight) would affect
the variability of the results. Analyses were initially of
sputum biomarkers that were significantly changed in the
pre-specified analyses and were then extended to all
sputum biomarkers. Further post-hoc analyses were per-
formed to determine whether pooling the data from the
waking and post-waking samples would also reduce sample
variability. Pooled data were not adjusted for sputum
weight.
Ethical aspects
The study was conducted in accordancewith the Declaration
of Helsinki and the International Conference on Harmo-
nisation/Good Clinical Practice and received independent
ethics committee approval. All patients provided written
informed consent to participate in the study.
Results
Patients
The first patient was enrolled on 25 September 2008, and the
last patient completed on 20 April 2009. Patient disposition
is shown in Fig. 1. Of 69 patients enrolled, 38 patients were
randomised to treatment: 16 patients received placebo and
22 patients received AZD9668 60 mg bid. (Thirty-one
patients were not randomised: 4 due to AEs, 9 due to
voluntary withdrawal and 18 did not meet the eligibility
Figure 1 Patient disposition during the study. aUse of restricted antibiotic.
AZD9668 in patients with bronchiectasis 527criteria during the 3-week run-in period.) Treatment
compliance was >80% in both groups. Thirty-three (87%)
patients completed the study and no patient was excluded
from any analysis. One patient in the AZD9668 group used
a prohibited antibiotic, but a sensitivity analysis showed that
exclusion of this patient from the efficacy analysis set had no
effect on study outcome (data not shown).Table 1 Patient demographic and clinical characteristics at en
Tre
Pla
Age, years, median (range) 6
Gender, n (%)
Male
Female 1
Race, n (%)
White 1
Black or African American
Asian
Other
Weight, kg, median (range) 7
Height, cm, median (range) 16
BMI, kg/m2, median (range) 29.
Smoking history
Current, n (%)
Former, n (%)
First diagnosis of bronchiectasis, n (%)
24 months
>24 months 1
No date given
Type of bronchiectasis sputum
Mucoid
Purulent with non-Pseudomonas bacteria
Purulent with Pseudomonas bacteria
Concomitant medication, n (%)
LAMA
ICS/LABA
Azithromycin
bid Z twice daily; BMI Z body mass index; LAMAZ long-acting musc
beta agonist.Despite the block randomisation process, the two
treatment groups differed in certain demographic and
patient characteristics (Table 1), with a higher proportion
of males (59%) in the AZD9668 group than in the placebo
group (31%) and fewer patients in the placebo group taking
long-acting muscarinic antagonists (LAMA) (placebo, 6% vs
AZD9668, 41%), inhaled corticosteroid/long-acting betarolment (safety analysis set).
atment group
cebo (n Z 16) AZD9668 60 mg bid (n Z 22)
2 (54e73) 61 (42e79)
5 (31) 13 (59)
1 (69) 9 (41)
4 (88) 19 (86)
1 (6) 0 (0)
0 (0) 3 (14)
1 (6) 0 (0)
6 (63e99) 75 (48e111)
3 (149e177) 168 (155e188)
1 (23.5e34.7) 24.7 (17.6e46.2)
0 (0) 1 (5)
5 (31) 11 (50)
3 (19) 4 (18)
3 (81) 17 (77)
0 (0) 1 (5)
3 (19) 5 (23)
7 (44) 9 (41)
6 (38) 8 (36)
1 (6) 9 (41)
5 (31) 10 (45)
1 (6) 4 (18)
arinic antagonist; ICS/LABAZ inhaled corticosteroid/long-acting
Table 2 Measurements for primary outcome variables and sputum NE activity (efficacy analysis set).
Baseline measurements End of treatment measurements Comparison between AZD9668 and placebo
at end of treatment (ANCOVA)Placebo AZD9668 Placebo AZD9668
Sputum neutrophils n Z 11 (waking)
n Z 10
(post-waking)
n Z 19 (waking)
n Z 18
(post-waking)
n Z 11 (waking)
n Z 10
(post-waking)
n Z 19 (waking)
n Z 18
(post-waking)
Ratio 90% CI p-value
Waking sample, 106/g geometric
mean (CV, %)
5.63 (100.4) 6.57 (123.8) 5.34 (297.5) 6.5 (141.1) 1.06 0.59, 1.91 0.872
Post-waking sample, 106/g
geometric mean (CV, %)
5.19 (368.1) 6.69 (284.4) 5.75 (270.8) 7.05 (224.9) 1.07 0.55, 2.07 0.862
24-h sputum weight, g mean (SD) n Z 13 n Z 20 Change from
baseline n Z 13
Change from
baseline n Z 20
LSM difference
(SEM)
90% CI p-value
Weight, g mean (SD) 15.48 (9.663) 37.06 (39.61) 5.01 (18.37) 8.27 (18.72) 5.22 (5.693) 14.9, 4.46 0.367
Lung function tests n Z 13 n Z 20 Change from
baseline n Z 13
Change from
baseline n Z 20
LSM difference
(SEM)
90% CI p-value
FEV1, L mean (SD) 1.77 (0.377) 2.07 (0.798) 0.04 (0.082) 0.06 (0.100) 0.10 (0.034) 0.04, 0.16 0.006
SVC, L mean (SD) 2.74 (0.687) 3.38 (1.071) 0.06 (0.173) 0.06 (0.200) 0.13 (0.074) 0.01, 0.26 0.079
FVC, L mean (SD) 2.67 (0.680) 3.37 (0.994) 0.01 (0.174) 0.05 (0.227) 0.03 (0.080) 0.10, 0.17 0.674
FEF25e75%, L/s mean (SD) 1.08 (0.416) 1.16 (0.939) 0.01 (0.165) 0.08 (0.134) 0.07 (0.049) 0.01, 0.15 0.157
BronkoTest diary card variables n Z 16 n Z 21 Change from
baseline n Z 16
Change from
baseline n Z 21
LSM difference
(SEM)
90% CI p-value
PEF, L/min mean (SD)
Morning 312.8 (74.92) 364.4 (124.6) 2.06 (35.22) 2.11 (22.70) 9.05 (N/A) 7.14, 25.23 0.351
Evening 311.0 (73.09) 372.4 (132.7) 0.99 (35.79) 2.24 (23.38) 5.71 (N/A) 11.0, 22.46 0.568
Night time symptoms,a mean (SD) 0.76 (0.966)b 0.74 (1.035) 0.28 (0.920)b 0.15 (0.657) 0.11 (0.215) 0.25, 0.48 0.598
Breathing,a mean (SD) 2.08 (0.299) 2.07 (0.301) 0.01 (0.340) 0.07 (0.518) 0.05 (0.131) 0.27, 0.17 0.700
Sputum colour,a mean (SD) 3.44 (1.939) 3.85 (1.454) 0.13 (0.752) 0.17 (1.285) 0.12 (0.330) 0.44, 0.68 0.713
Sputum amount,a mean (SD) 2.17 (0.712) 2.57 (0.655) 0.13 (0.488) 0.12 (0.626) 0.09 (0.199) 0.25, 0.42 0.666
How do you feel?,a mean (SD) 2.22 (0.225) 2.03 (0.305) 0.17 (0.447) 0.04 (0.531) 0.05 (0.153) 0.21, 0.31 0.731
How often do you cough?,a mean (SD) 1.57 (0.716) 1.30 (0.689) 0.16 (0.520) 0.02 (0.571) 0.11 (0.184) 0.20, 0.42 0.549
Reliever medication use,a mean (SD) 0.96 (1.979) 1.94 (3.816)c 0.04 (0.143) 0.16 (0.581)c 0.22 (0.152) 0.04, 0.47 0.165
SGRQ-C score n Z 13 n Z 19 Change from
baseline n Z 13
Change from
baseline n Z 19
LSM difference
(SEM)
90% CI p-value
Symptoms, mean percent (SD) 68.91 (13.80) 66.18 (16.13) 1.8 (11.49) 7.2 (18.60) 6.02 (5.947) 16.1, 4.10 0.320
Activity, mean percent (SD) 52.20 (29.96) 37.75 (24.63) 0.6 (13.31) 3.5 (14.06) 5.55 (5.278) 14.5, 3.43 0.302
Impact, mean percent (SD) 38.17 (23.15) 31.22 (19.68) 2.3 (13.87) 6.3 (13.84) 5.74 (5.001) 14.2, 2.77 0.261
Overall, mean percent (SD) 47.93 (21.22) 39.42 (17.90) 1.3 (11.04) 5.6 (13.15) 5.64 (4.651) 13.5, 2.27 0.236
Sputum NE activity n Z 12 n Z 20 n Z 12 (waking)
n Z 12
(post-waking)
n Z 20 (waking)
n Z 19
(post-waking)
Ratio 90% CI p-value
(continued on next page)
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Figure 2 Ratio of absolute and percentage neutrophil cell
counts for AZD9668 versus placebo at Day 28. CI Z confidence
interval.
AZD9668 in patients with bronchiectasis 529agonists (ICS/LABA) combinations (placebo, 31% vs
AZD9668, 45%) and/or azithromycin (placebo, 6% vs
AZD9668, 18%). Baseline lung function, neutrophil counts,
24-h sputum weight and NE activity were all lower in the
placebo group than in the AZD9668 group (Table 2), and
percentage predicted FEV1 values at the enrolment and
randomisation visits were slightly higher in the placebo
group (mean [standard deviation]% predicted FEV1 for
placebo, 76.1 [22.1] vs 72.0 [23.9] for AZD9668).Efficacy
Primary efficacy variables
Absolute and percentage neutrophil cell count in sputum
For patients who completed the study, analysis of the
absolute and percentage sputum neutrophil cell counts
showed that there was no significant difference between
AZD9668 and placebo at Day 28 for either the waking or
post-waking samples (Table 2 & Fig. 2). Individual patient
data showed that the changes from baseline in both
neutrophil counts and percentage neutrophils were vari-
able in magnitude and direction (data not shown).
24-h sputum weight
The mean sputum weight in the AZD9668 group decreased
from 37.06 g by 8.27 g, versus an increase of 5.01 g from
baseline of 15.48 g in the placebo group, although the
changes were not statistically significant due to the wide
confidence intervals (least squares means [LSM] difference:
5.22, 90% CI 14.9, 4.46; p Z 0.367) (Table 2).
Lung function tests
In the AZD9668 group (n Z 20) there were increases from
randomisation in the mean values for FEV1, SVC, FVC and
FEF25e75% at Day 28, whereas in the placebo group (nZ 13)
(except for FEF25e75%), there were decreases from ran-
domisation (Table 2).
ANCOVA indicated that the improvements from baseline
in FEV1 and SVC were significantly greater for AZD9668 than
placebo (p Z 0.006 for FEV1 and p Z 0.079 for SVC,
Table 2). FVC and FEF25e75% increased on AZD9668 and
530 R. Stockley et al.declined on placebo, but these differences were not
statistically significant (Table 2).
BronkoTest diary card symptoms
While small increases in morning PEF did occur for AZD9668,
there was no statistically significant difference between
AZD9668 and placebo (Table 2). There were also no statisti-
cally significantdifferences betweentreatments for thediary
card symptom scores or use of reliever medication (Table 2).
St George’s Respiratory Questionnaire scores
Mean changes from randomisation to end of treatment in
SGRQ-C scores in the AZD9668 and placebo groups are
shown in Table 2. The LSM difference between AZD9668 and
placebo exceeded 4 units for the SGRQ-C overall score and
for each individual domain, indicating changes of clinical
relevance.19 However, due to wide CIs, these differences
were not statistically significant.
Secondary efficacy variables
AZD9668 exposure in plasma and sputum
AZD9668wasmeasurable in plasmaonDay 28 fromall treated
patients both pre-dose and 1e2 h after dosing (pre-dose:
geometric mean 274.6 nM, covariate [CV] 98.2%; 1e2 h post-
dose: geometric mean 1377.6 nM, CV 28.5%). These data are
summarised in Fig. 3. Gmean values for AZD9668 in sputum at
Day 28 pre-dose and 1e2 h after dosing were 62.9 nM (CV
151%) and 96.5 nM (CV 179%), respectively (Fig. 3).
NE activity in sputum
NE activity in both the waking (placebo n Z 12, AZD9668
nZ 20) and post-waking (placebo nZ 12, AZD9668 nZ 19)
sputum samples decreased from baseline in individuals
receiving AZD9668 compared with an increase in individuals
receiving placebo; however, the CI was wide and overall
differences between AZD9668 and placebo were not
statistically significant (Table 2). The NE activity at baseline
and the changes from baseline varied markedly between
patients in both groups, for both the waking and post-
waking samples.
Inflammatory and tissue degradation markers
Values at randomisation and the changes from random-
isation in inflammatory and tissue degradation markersFigure 3 Pre-dose and 1e2 h post-dose concentration of
AZD9668 in plasma and sputum at Day 28 for patients in the
AZD9668 group.varied markedly between patients in both the placebo
(n Z 12) and AZD9668 groups (n Z 20). For sputum
biomarkers, IL-6 and RANTES in the post-waking sputum
sample decreased with AZD9668 (ratio AZD9668 to placebo:
0.72, 90% CI 0.52, 1.00; p Z 0.098 and 0.63, 90% CI 0.46,
0.86; p Z 0.018 respectively). For blood biomarkers, IL-8
showed a decrease with AZD9668 (ratio: 0.74, 90% CI
0.56, 0.99; pZ 0.085). There was no significant difference
between AZD9668 and placebo in urine desmosine levels
(free or total) or plasma desmosine levels (Table 2 of the
Supplementary Material).
Post-hoc analyses
Adjusting for sputum weight had no effect on the post-
waking results for change over the course of the study in IL-6
and RANTES: IL-6 adjusted (ratio: 0.63, 90% CI 0.40, 0.99;
pZ 0.094); RANTES adjusted (ratio: 0.58, 90% CI 0.38, 0.90;
p Z 0.042) (Fig. 4). Indeed, in most cases CVs (variability)
were slightly higher for values adjusted for sputumweight. A
similar lack of impact of adjusting for sputum weight was
seen for the other biomarkers. In addition, variability was
only slightly reduced when the results of the waking and
post-waking samples were pooled, and this had no effect on
the interpretation of the data.
Safety
Overall, the incidence of AEs was higher in the placebo
group (94%) than the AZD9668 group (68%). There were no
deaths or treatment-related serious AEs. One patient in
each treatment group discontinued due to AEs: low mood,
lethargy, neck swelling, sleep disorder and increased
appetite (placebo) and exacerbation of bronchiectasis
(AZD9668).
There were more respiratory symptoms reported on
placebo and more nervous system symptoms and infections
(mostly nasopharyngitis) on AZD9668. Table 3 shows that
the most commonly reported AEs were headache (2/16
[13%] placebo and 7/22 [32%] AZD9668), diarrhoea (4/16
[25%] placebo and 2/22 [9%] AZD9668) and nasopharyngitis
(0/16 [0%] placebo and 4/22 [18%] AZD9668).
No clinically relevant changes in clinical chemistry,
haematology, urinalysis, vital signs, ECG, physical exami-
nation or sputum bacteriology were observed. In one
patient, transaminases increased during treatment with
AZD9668, began to improve prior to last dose of study drug
and returned to baseline on further monitoring once off
study medication; there were no associated symptoms and
bilirubin remained normal, but a relationship to study drug
could not be excluded.Discussion
This was a signal-searching study of AZD9668, a novel orally
active NE inhibitor, in patients with bronchiectasis. Bron-
chiectasis was chosen due to the high and persistent levels
of NE activity in sputum in this condition.20 A number of
clinical and biomarker variables that could potentially
reflect the result of NE inhibition were assessed. We did not
demonstrate that 28 days of AZD9668 (60 mg bid) altered
the sputum neutrophil counts, although the sputum
neutrophil elastase activity had decreased numerically (not
Table 3 Treatment emergent adverse events occurring in
5% of patients (safety analysis set).
MedDRA preferred term n (%) patients
Placebo
(n Z 16)
AZD9668
60 mg bid
(n Z 22)
Headache 2 (13) 7 (32)
Diarrhoea 4 (25) 2 (9)
Nasopharyngitis 0 (0) 4 (18)
Peripheral oedema 2 (13) 1 (5)
Constipation 2 (13) 0 (0)
Oropharyngeal pain 2 (13) 0 (0)
Musculoskeletal
chest pain
0 (0) 2 (9)
Contusion 0 (0) 2 (9)
Lethargy 1 (6) 1 (5)
Upper abdominal pain 1 (6) 1 (5)
Nausea 1 (6) 1 (5)
Vomiting 1 (6) 1 (5)
Back pain 1 (6) 1 (5)
Haemoptysis 1 (6) 1 (5)
MedDRA Z Medical Dictionary for Drug Regulatory Affairs.
Figure 4 Post-hoc analysis: ratio of change from random-
isation to Day 28 in sputum biomarkers for AZD9668 versus
placebo e data unadjusted versus adjusted for sputum weight.
ILZ interleukin; RANTESZ Regulated on Activation, Normal T
Expressed and Secreted; TNF Z tumour necrosis factor; MCP-
1 Z monocyte chemoattractant protein-1; LTB-
4 Z leukotriene B4.
AZD9668 in patients with bronchiectasis 531statistically significant) at the end of treatment. There was,
however, a significant increase in lung function in the
AZD9668 group (a difference of 100 mL in FEV1 and
a difference of 130 mL in SVC compared with placebo).
There were also non-significant trends favouring AZD9668
for FVC, FEF25e75%, morning PEF, 24-h sputum weight,
SGRQ-C (all scores) and for most inflammatory biomarkers,
especially in the post-waking sputum samples. There were
no differences between AZD9668 and placebo for
BronkoTest diary card symptom variables, reliever medi-
cation use and markers of tissue degradation.
The significant change in prebronchodilator FEV1 in such
a short study reflects a process independent of bronchodi-
lation and is the kind of change seen after sputum clear-
ance following antibiotic treatment21 suggesting it reflects
a different pathological process. However, in contrast, no
significant changes in lung function tests were seen ina 12-month study of nebulised gentamicin22 even though
sputum purulence, elastase and time to first exacerbation
did improve. This may indicate that targeting certain
aspects of the disease process, such as with an anti-
inflammatory therapy, may offer different benefits from
those offered by antimicrobials.
Two recently-published Phase II studies showed that
AZD9668 did not improve lung function or respiratory signs
and symptoms in patients with COPD.23,24 The findings of
the current study might have predicted the negative find-
ings in COPD as NE activity is lower than in bronchiectasis so
any benefit of AZD9668 would have been less marked and
much slower to see. The potential masking effect of
budesonide/formoterol in the second COPD study may also
have contributed to the lack of effect.
While it is possible that higher concentrations of AZD9668
maybe required to inactivateNEcompletely in the airways, in
this study, AZD9668 was present in plasma and sputum
supernatants at concentrations predicted to inhibit NE in the
lung tissue. The IC50 for NE inhibition in in vitro assays is
between 44 and 50 nM15 and these levels were exceeded in
both the plasma and sputum of most patients in this study. As
such, the absence of any significant effect on NE activity or
sputum neutrophil cell count is likely due to the large inter-
patient variability in these data, especially as a non-
significant trend for reduced NE activity was observed in
AZD9668-treated patients. Furthermore, NE has been shown
to play a role in mucus release25; therefore, it is possible that
AZD9668 could have improved lung function via inhibition of
NE and a resulting decrease in mucus secretion. This hypoth-
esis would be partially supported by our observation of a non-
significant trend for the reduction of 24-h sputum weight in
the AZD9668 group versus an increase in the placebo group. In
addition, inhibition of NEbyAZD9668mayhave improved lung
function via an improvement in mucociliary clearance.3
532 R. Stockley et al.While a direct effect of AZD9668 on NE activity in
patients with bronchiectasis was not confirmed by our data,
the observed trend for a decrease in NE activity is in line
with that of another Phase IIa study assessing the efficacy
of AZD9668 in cystic fibrosis,26 which also showed a non-
significant trend to reduced NE activity on active drug.
One problem in the interpretation of sputum data in small
studies is the large variability. Even though the assay vali-
dation was designed to minimise the analytical variation
and any matrix interference, other technical factors such
as sputum processing will have some effect. However, the
major feature that contributes is large intra- and inter-
patient variability seen even with sputum collection over
longer periods than undertaken here, which will include
variable dilution with nasopharyngeal secretions and
airways hydration. Recent data have shown that with longer
collection periods (over 4 h) and sequential daily sampling
intrapatient variability can be reduced, optimised by using
the average of at least 3 days’ consecutive data.27 This
approach should be used in future studies to increase the
power and/or reduce the number of patients needed.
Despite the variability, the trend for reductions in
inflammatory markers in the AZD9668 group versus placebo
was significant for post-waking sputum IL-6 and RANTES as
well as plasma IL-8. Reductions in IL-8 and RANTES may be
associated with the ability of NE to affect IL-8 and RANTES
expression through regulation of nuclear factor kappa-light-
chain-enhancer of activated B cells (NF-kB).10,28e31 Simi-
larly, in vitro studies using NE inhibitors support the link
between NE and increased IL-6 production.32,33 However,
these data must be interpreted with caution, as the
changes were generally small, with large variability within
and between patients which was unaffected by adjusting
for sputum weight or by pooling samples. Furthermore,
statistical significance was not adjusted for multiple testing
and the exploratory threshold p-value (p < 0.1) is associ-
ated with a substantially increased risk of chance findings,
particularly given the number of sputum inflammatory
marker assessments undertaken.
This study was limited by its small size, which probably
resulted in a lack of precision in the mean estimates. In
addition, the small numbers of patients recruited by some
centres, together with randomisation in blocks of 4, may
have contributed to some of the imbalance of the baseline
characteristics. It is difficult to determine whether the
baseline differences in lung function and the greater
frequency of use of bronchodilator medications in the
AZD9668 group could have contributed to the observed
differences in lung function from placebo. Some of these
baseline differences, however, were taken into account in
the statistical analyses by including the baseline value as
a covariate in the analysis of covariance, and others were
considered unlikely to have had an impact on the outcome
of the study.
In conclusion, despite the short duration of treatment,
AZD9668 demonstrated some signals indicative of potential
clinical efficacy in patients with bronchiectasis. AZD9668
was also well tolerated at a dose of 60 mg twice daily given
for 28 days. However, given the significant inter- and intra-
patient variability in inflammatory markers and neutrophil
elastase levels, confirmation of these findings will require
larger studies of longer duration.Acknowledgement
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